L
Lorenz Trümper
Researcher at University of Göttingen
Publications - 276
Citations - 22696
Lorenz Trümper is an academic researcher from University of Göttingen. The author has contributed to research in topics: Lymphoma & Diffuse large B-cell lymphoma. The author has an hindex of 53, co-authored 260 publications receiving 19534 citations. Previous affiliations of Lorenz Trümper include Deutsche Forschungsgemeinschaft & University of Cologne.
Papers
More filters
Journal ArticleDOI
The EHA Research Roadmap: Malignant Lymphoid Diseases
Martin Dreyling,Marc André,Nicola Gökbuget,Hervé Tilly,Mats Jerkeman,John G. Gribben,Andrés J.M. Ferreri,P. Morel,Stephan Stilgenbauer,C. Fox,Josep-Maria Ribera,Sonja Zweegman,Igor Aurer,Csaba Bödör,Birgit Burkhardt,Christian Buske,Maria Dollores Caballero,E Jean Hartigan del Campo,Bjoern Chapuy,Andrew Nicholas Davies,Laurence de Leval,Jeanette K. Doorduijn,Massimo Federico,Philippe Gaulard,Francesca Gay,Paolo Ghia,Kirsten Grønbæk,Hartmut Goldschmidt,Marie José Kersten,Barbara Kiesewetter,Judith Landman-Parker,Steven Le Gouill,Georg Lenz,Sirpa Leppä,Armando López-Guillermo,ElizabethH. Macintyre,Maria Victoria Mateos Mantega,Philippe Moreau,Carol Moreno,Bertrand Nadel,Jessica Okosun,Roger L. Owen,Šárka Pospíšilová,Christiane Pott,Tadeusz Robak,M.S. Spina,Kostas Stamatopoulos,Jan Stary,Karin Tarte,Allessandra Tedeschi,Catherine Thieblemont,Ralf Ulrich Trappe,Lorenz Trümper,Gilles Salles +53 more
TL;DR: Normal Hematopoiesis; Malignant Lymphoid Malignant Myeloid Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Transfusion in HematOPoietic Stem Cell Transplantation; CAR-T and Other Cell- based Therapies; and analyzes including immunother- apies will be increasingly implemented should improve the prognosis of high-risk patients but also significantly reduce treatment-related morbidity.
Journal ArticleDOI
Retroperitoneal fibrosis as manifestation of chronic GVHD after allogeneic hematopoietic SCT.
TL;DR: Retroperitoneal fibrosis as manifestation of chronic GVHD after allogeneic hematopoietic SCT is described.
Journal ArticleDOI
The Prognostic Impact Of Gene Rearrangements and Protein Expression Of MYC, BCL2 and BCL6 In Young High-Risk Patients With DLBCL
Heike Horn,Marita Ziepert,Thomas F. E. Barth,Heinz-Wolfram Bernd,Martin Wartenberg,Alfred C. Feller,Wolfram Klapper,Michael Hummel,Harald Stein,Dido Lenze,Sylvia Hartmann,Martin-Leo Hansmann,Peter Möller,Sergio Cogliatti,Michael Pfreundschuh,Lorenz Trümper,Markus W. Löffler,German Ott,Norbert Schmitz,Andreas Rosenwald +19 more
TL;DR: Rearrangements of MYC and BCL2 seem to be relevant prognostic factors also in young high-risk patients, and it seems unlikely that the rearrangements described here (completely) explain the poor prognosis of young, high- risk patients.
Journal ArticleDOI
Massive intrafollicular and arterial hyalinosis of the spleen following rituximab and methylprednisolone therapy in a patient with splenic marginal zone lymphoma.
Inga-Marie Schaefer,Alexander Marx,Christian Sauer,Karin Hohloch,B. Michael Ghadimi,Lorenz Trümper,Philipp Ströbel +6 more
TL;DR: This poster presents a poster presented at the 2016 China oncology congress of the American Association for the Advance Study of Oncology (AAS) entitled “Advances in Radiology and Pathology: Foundations of Post-operative Care Quality Assurance and Efficacy”.
Journal ArticleDOI
TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
Swaminathan Padmanabhan Iyer,Lorenz Trümper,Owen A. O'Connor,Barbara Pro,Timothy M Illidge,Ranjana H. Advani,Nancy L. Bartlett,Jacob Haaber Christensen,Franck Morschhauser,Eva Domingo-Domenech,Giuseppe Rossi,Won Seog Kim,Tatyana Feldman,Tobias Menne,David Belada,Árpád Illés,Kensei Tobinai,Kunihiro Tsukasaki,Su-Peng Yeh,Andrei R. Shustov,Andreas Hüttmann,Kerry J. Savage,Sam Yuen,Pier Luigi Zinzani,Harry Miao,Veronica Bunn,Keenan Fenton,Michelle A. Fanale,Markus Puhlmann,Steven M. Horwitz +29 more
TL;DR: At this important 5-year milestone, A+CHP still provides clinically meaningful improvement in both PFS and OS versus CHOP, with a manageable safety profile, including continued resolution/improvement of PN.